Universal Drugstore logo

Is Zepbound a GLP-1? Understanding Its Role in Weight Loss and More

In the realm of weight loss medications, questions often arise about how different drugs function and what category they fall into. One such medication is Zepbound (tirzepatide), which has gained attention for its distinctive approach to weight management. So, what exactly is Zepbound, and is it classified as a GLP-1?

In This Article

What is Zepbound?

Zepbound is a medication that is FDA-approved for weight management. Its active ingredient, tirzepatide, helps individuals manage their weight by impacting the mechanisms that control hunger and metabolic processes. It mimics natural hormones in the body, mainly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action is particularly effective in reducing appetite and supporting blood sugar regulation.

Is Zepbound a GLP-1?

Despite it being sometimes referred to as one, Zepbound is not just a GLP-1 receptor agonist, which includes medications like Ozempic and Wegovy. Instead, it belongs to a unique, dual-action drug class known as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. By working on both GIP and GLP-1 receptors, it typically leads to greater weight loss than traditional GLP-1s.

How Does Zepbound Work?

Zepbound works by mimicking the hormones GLP-1 and GIP. These hormones play key roles in regulating several bodily functions, including:

  • Appetite Regulation: It targets brain areas that control hunger, reducing the desire to eat and decreasing cravings. It also slows gastric emptying (how fast food leaves your stomach), making you feel fuller faster, so you eat less.
  • Metabolism: By enhancing insulin secretion, it helps manage blood sugar levels.
  • Fat Storage: Clinical studies indicate significant reductions in visceral fat (fat around organs) and waist circumference.

As with many medications, Zepbound faces several trends and challenges.

Insurance and Coverage: Its coverage is often variable. For instance, some providers exclude Zepbound for obesity treatment but will cover Mounjaro, which contains the same active ingredient, for diabetes management. Additionally, new formulary strategies, including generics prioritization, are impacting accessibility.

Expanding Indications: Beyond obesity, Zepbound is being explored for cardiovascular risk reduction, heart failure, and even Alzheimer’s disease management.

Common and Rare Side Effects

When considering Zepbound, understanding potential side effects is crucial.

Common Side Effects:

  • Gastrointestinal issues like nausea, diarrhea, or constipation.
  • Fatigue and general discomfort, which tend to resolve with time.

Serious but Rare Side Effects:

  • Kidney damage.
  • Gallbladder problems, including gallstones.
  • Pancreatitis.
  • Increased risk of low blood sugar, particularly if used along with insulin or an insulin secretagogue.
  • Vision changes or loss, especially in those with diabetic retinopathy.
  • In rare instances, increased suicidal thoughts, with the FDA closely monitoring these reports.

Considering Alternatives

If you’re comparing Zepbound with other medications, options like Wegovy and Ozempic (semaglutide) may come up due to their similar uses in obesity management. Each medication has distinct characteristics. For instance, Wegovy is a GLP-1 RA specifically approved for weight loss while also being researched for other medical uses such as metabolic conditions.

Concluding Thoughts

Zepbound stands out as a dual receptor agonist affecting both GLP-1 and GIP receptors, expanding its impact beyond traditional GLP-1 medications. While generally used in weight management, research is continually evolving, opening the door for new therapeutic indications.

If you’re interested in exploring more about how medications like Zepbound are classified and what alternatives exist, visit the drug classes page to learn about different treatment options available.

Sources